Scarica l'app Stockscreener
237.95
0.71%
1.67
Dopo l'orario di chiusura:
237.95
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Jazz Pharmaceuticals plc (JAZZ) Stock forecasts - uk.finance.yahoo.com
Jazz Pharmaceuticals stock reports record Q2 revenue growth - AD HOC NEWS
JAZZ Reinstated by Goldman Sachs -- Price Target Set at $337 - gurufocus.com
Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating By Investing.com - Investing.com UK
JAZZ Looks 56.8% Overvalued on GF Value™ as Insider Selling Pers - gurufocus.com
Jazz Pharmaceuticals PLC (J7Z.HA) Analyst insights, Price targets and Recommendations - uk.finance.yahoo.com
Jazz Pharmaceuticals plc (JAZZ) Stock Forecasts - Yahoo Finance
Jazz Pharmaceuticals Extends And Reprices $1.895 Billion Term Loan B To 2033 - TradingView
Five more years to repay its loans: Jazz Pharmaceuticals (JAZZ) also lowers borrowing margins. - Stock Titan
Jazz Pharmaceuticals (JAZZ) Gains Put Its Valuation Story Back In Focus - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - sg.finance.yahoo.com
Chumi Khurana Recognized by the Asian American Business Development Center in Partnership With America250Jazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals plc (JAZZ) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
Jazz Pharmaceuticals stock holds near USD 241.46 as results shape the outlook - AD HOC NEWS
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: A Biotech Powerhouse with 20% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B - Yahoo Finance
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands - Yahoo Finance
What Makes the Latest Jazz Pharmaceuticals (JAZZ) Story Different? - Kalkine Media
Jazz Pharmaceuticals PLC (JAZZ) Stock Price Target & Forecast - TradingKey
Ajit Baid Joins Jazz Pharmaceuticals as Executive Director, Head of Marketing – EMD Franchise - hrtoday.in
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? - fool.com
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet - Yahoo Finance
Jazz Pharmaceuticals PLC at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences - BioBuzz
Jazz Pharmaceuticals PLC at Deutsche Bank HealthCare Summit Transcript - gurufocus.com
Form 8K Jazz Pharmaceuticals plc For: 15 September By Investing.com - Investing.com South Africa
JAZZ: Oncology and portfolio growth drive raised guidance, with zanidatamab leading future expansion - TradingView
Jazz Pharmaceuticals completes Actio Biosciences acquisition - Investing.com
Jazz Pharmaceuticals completes Actio Biosciences acquisition By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences - PR Newswire
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: An 18% Upside Potential Beckons Investors - DirectorsTalk Interviews
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says - marketscreener.com
JAZZ Maintained by UBS -- Price Target Raised to $337 - GuruFocus
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval - Investing.com
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com India
UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating - marketscreener.com
Jazz Pharmaceuticals SVP Mary Elizabeth Henderson Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com Nigeria
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):